with ADCA type III, including two new families, we found that a common "founder" haplotype is seen in a more restricted 3.8-Mb region, spanning markers GGAA05 and D16S3095. We present here a newly refined critical interval of 16q-ADCA type III/SCA4. Data of 11 new DNA markers on 16q22.1 would also be useful for other research of genes mapped to this region.
Introduction
Autosomal dominant cerebellar ataxia (ADCA) is a group of heterogeneous neurodegenerative disorders (Harding 1982) . It is clinically characterized by progressive cerebellar ataxia, although other extracerebellar signs, such as pyramidal or extrapyramidal signs, ophthalmoparesis, amyotrophy, and peripheral neuropathy may be variably present. ADCA is classified into three types on the basis of its clinical features (Harding 1982) . ADCA types I and II are clinically characterized by prominent extracerebellar signs and macular dystrophy, respectively. In contrast, ADCA type III is characterized by purely cerebellar ataxia throughout the course of illness (Harding 1982; Ishikawa et al. 1996) .
At present, 18 loci have been reported to be responsible for ADCA, although there are still other families that do not map to any of these loci. Among these disorders, causative genes have been further identified as expansions of a trinucleotide (CAG) repeat for SCA1 (Orr et al. 1993) , SCA2 (Imbert et al. 1996; Sanpei et al. 1996) , MachadoJoseph disease/SCA3 (Kawaguchi et al. 1994) , SCA6 (Zhuchenko et al. 1997) , SCA7 (David et al. 1997) , SCA12 (Holmes et al. 1999) , SCA17 (Koide et al. 1999; Nakamura et al. 2001 ) and dentatorubral and pallidoluysian atrophy (DRPLA) (Nagafuchi et al. 1994) . Spinocerebellar ataxia type 8 has been proposed to be caused by the expansion of a CTG repeat in the 3Ј noncoding region of the SCA8 gene (Koob et al. 1999) , and the SCA10 mutation has been demonstrated to be the expansion of the pentanucleotide ATTCT repeat in an intron of this gene (Matsuura et al. 2000) . Only the gene loci have been identified for the remaining 8 SCAs: SCA4 on 16q22.1 (Gardner et al. 1994; Flanigan et al. 1996) , SCA5 on 11 cen (Ranum et al. 1994 ), SCA11 on 15q14-q21.3 (Worth et al. 1999) , SCA13 on 19q13.3-q13.4 (Herman-Bert et al. 2000) , SCA14 on 19q13.4-q ter (Yamashita et al. 2000) , SCA16 on 8q22.1-q24.1 (Miyoshi et al. 2001) , SCA19 (Verbeek et al. 2002) , and SCA21 (Vuillaume et al. 2002) .
We previously mapped a gene responsible for ADCA type III to chromosome 16q (Nagaoka et al. 2000) . The region spans a 10.9-cM region flanked by D16S3089 and D16S515, the locus identical to the SCA4 locus (Gardner et al. 1994; Flanigan et al. 1996) . We further identified that our "16q-linked ADCA type III" has a common founder haplotype for markers between D16S3043 and D16S3095 in this region (Takashima et al. 2001) .
To identify the causative gene mutation for 16q-linked ADCA type III, we first constructed a physical map spanning D16S3043 and D16S3095 because no complete physical maps had been available. We found 11 new polymorphic markers in this region. Using these markers, we analyzed the haplotype of eight families and narrowed the critical region.
We searched tandem repeats in this candidate region for any abnormal expansion in our patients, because expansions of certain repeat sequences, such as CAG/CTG or ATTCT repeats, are the only causative mutations for SCAs.
Here we show a complete bacterial artificial chromosome (BAC) contig of the locus for 16q-linked ADCA type III, information of newly developed markers in this region, and results of haplotype analysis.
Patients and methods

Patients and families
Eight families were studied, six of which have been previously described (Ishikawa et al. 1996; Nagaoka et al. 2000; Takashima et al. 2001) . Two other families have been included for the first time in this study because they also showed later-onset pure cerebellar ataxia with autosomal dominant inheritance (family trees are available on request). From our interviews with family members, we determined that these two families originated from the Tokyo Metropolitan area (T1) and the Gunma Prefecture (T2), indicating that none of our eight families are related.
Thirty-eight Japanese individuals whose family members have no history of neurodegenerative diseases were chosen as normal controls.
A peripheral blood sample was obtained with informed consent from each family member and control individual, and genomic DNA was extracted as previously described (Ishikawa et al. 1996) .
Construction of the BAC contig BAC clones were initially searched from National Center for Biotechnology Information (NCBI) genome sequencing contigs (http://www.ncbi.nlm.nih.gov/genome/seq) by microsatellite DNA markers linked to the critical interval. By this method, we obtained eight BAC clones, Rp11-123C5, Rp11-112G1, Rp11-361L15, Rp11-167P11, Rp11-292B23, Rp11-521L9, Rp11-502K10, and Rp11-311C24, from Research Genetics (Houtsville, AL, USA).
DNA from each BAC clone was extracted by a modified QIAGEN Plasmid Mini Purification Protocol (QIAGEN, Hilden, Germany). BAC clones were first confirmed to contain microsatellite DNA markers or Sequence targged site (STS) markers by polymerase chain reaction (PCR). These clones were then "end-sequenced" by T7 (5Ј-ATACGAC TCACTATA-3Ј) and Sp6 (5Ј-ATTTAGGTGACACTA TA-3Ј) primers.
We 
Sequencing
Sequencing reactions were performed using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems, Foster City, CA, USA). We cycle-sequenced 2-3 µg BAC DNA for 50 cycles with 6.4 pmol of either T7 or Sp6 primer on an ABI GeneAmp PCR system 9700 (PE Applied Biosystems).
For genomic DNA, 10 ng PCR product was cyclesequenced for 25 cycles with 3.2 pmol of each primer. Nucleotide sequences were analyzed on an ABI PRISM 377 DNA Sequencer (PE Applied Biosystems).
Searching nucleotide-repeat variation
We derived the BAC clone sequence from NCBI (http:// www.ncbi.nlm.nih.gov/entrez). To identify tandem repeats, namely, 2 (di-), 3 (tri-), 4 (tetra-), 5 (penta-), and 6 (hexa-) tandem repeats, we used the RepeatMasker program. Oligonucleotide primers were then designed to amplify the genomic DNA segment flanking each repeat. PCR was performed in a final volume of 20 µl, containing 10 ng of genomic DNA, 3.4 pmol of each primer, 2.5 mM each of deoxyribonucleoside triphosphates, and 0.75 unit of Taq polymerase (Takara, Tokyo, Japan) or Gold Taq polymerase (Applied Biosystems Ampli-Taq Gold with Gene Amp).
The PCR products were separated on 2% agarose gel. To precisely genotype each DNA sample, we labeled the 5Ј end of the forward primer with fluorescent isothiocyanate, and amplified it. PCR products were separated on the Automated DNA Sequencer II (ALF, Pharmacia Biotech, Umea, Sweden) and analyzed with ALF Win Manager as previously described (Ishikawa et al., 1996; Ishikawa et al. 1997) . Eleven new markers with the highest polymorphism were then selected for genotyping and analysis for association with disease.
Haplotype analysis and linkage disequilibrium
Haplotype analysis was performed with 22 markers, including the 11 new markers, that showed enough polymorphism: 16q cen-D16S3043, D16S3031, CTATT01, TAGA02, GGAA05, D16S3086, TTCC01, GATA01, D16S421, TTTA001, CATG003, D16S3085, D16S3107, AAT01, D16S3025, TCTA01, CTTT01, D16S496, D16S3067, D16S3141, GT01, and D16S3095 16q ter-, in the order shown on our physical map (Fig. 1) . We analyzed genotypes of all available subjects, including those who married into these families. Because the 22 markers spaced in a distance of approximately 5 Mb, we reconstructed haplotypes in every family that showed minimum recombination events. The association of disease phenotype and each allele was statistically analyzed by Fisher's exact probability test.
Results
Construction of a BAC-based physical map contig
A complete contig spanning markers D16S3043 and D16S3095 was constructed with 38 BAC clones (Fig. 1) . The size of this contig was estimated to be no more than 4.8 Mb from the database ENSEMBL. According to the most recent NCBI database, 25 of the 38 BAC clones (65%) have been completely sequenced. On the other hand, the sequence of one BAC clone, TIGR 1109D8, is unknown. The remaining 12 BAC clones have some gaps in their sequences as of March 2002, although approximately 70% of their entire inserts have been published in a draft sequence version. Therefore, the nucleotide sequences of approximately 90% of the entire contig is now available.
According to the NCBI and ENSEMBL databases, at least 100 annotated genes are present within the candidate region, and 65 of them are expressed in the human brain.
Identification of repeat sequences
To search anonymous repeat sequences by RepeatMasker, we first had to know how powerful this software was in detecting tandem repeats. We inserted known tandem repeats with different repeat units in the known 6-kb nucleotide sequences, and applied the software program. By this test, we found that the software sufficiently detects dinucleotide repeats with more than nine repeat units, trinucleotide repeats with more than six repeat units, tetranucleotide repeats with more four repeat units, and penta-or hexanucleotide repeats with more than three repeat units (Table 1) .
We next applied this software to each BAC contig and found 146 dinucleotide, 83 trinucleotide, 213 tetranucleotide, and 91 penta-or hexanucleotide repeats in the entire sequenced region (Table 2 ). These repeats were confirmed to be unique by checking the flanking sequences. This would indicate that there are more than 500 tandem repeats within the entire contig.
Identification of 11 new polymorphic markers in 16q22.1 Among approximately 500 tandem repeats, we first selected repeats with higher numbers of repeat units, because repeats with larger repeat units tend to be more polymorphic. From this context, we chose 14 dinucleotide repeats that have more than 19 repeat units (Table 1) . Similarly, we chose 37 trinucleotide repeats that have more than 6 repeat units, except for ATT/TAA repeats; 32 tetranucleotide repeats with more than 9 repeat units; and 9 penta-or hexanucleotide repeats with more than 4 repeat units. For ATT/TAA repeats, we chose 2 repeats that have more than 14 repeat units. We examined whether these 94 markers were polymorphic.
When 38 normal Japanese individuals were genotyped, 26% of the tested repeats were demonstrated to be polymorphic: 12 dinucleotide, 1 trinucleotide, 10 tetranucleotide, and 1 pentanucleotide.
Among these 24 repeats, we selected the most polymorphic 11 repeats as "new" markers to analyze haplotypes in patients with ADCA type III (Tables 3, 4, 5). The sequences of primers of these 11 markers are described in Table 3 , and the size of PCR products and allele frequencies among 38 control individuals are described in Table 4 .
Haplotype and association analyses
Haplotypes of eight 16q-linked ADCA type III families are shown in Table 5 . The P4 family from our previous study (Ishikawa et al. 1997; Nagaoka et al. 2000; Takashima et al. 2001 ) had the haplotype 3(316 bp)-5(194 bp)-6(260 bp), which was different from the haplotype of other 11/100 1/37 2/9 Trinucleotide (CAG/GTC)n (CGG/GCC)n (CAA/GTT)n (TAA/ATT)n 39/83 9/9 4/7 16/24 6/38 (ATG/TAC)n (ACC/TGG)n (TCC/AGG)n 0/1 3/3 1/1 Tetranucleotide (TTCC/GGAA)n (TTCA/AAGT)n (TAAA/ATTT)n (TTTG/AAAC)n (TGGA/ACCT)n 32/213 10/16 6/14 2/89 0/42 2/13 (GGGT/CCCA)n (CAAT/GTTA)n (TCCC/AGGG)n (TCTA/AGAT)n 0/1 1/6 1/4 1/3 (TTTC/AAAG)n (CATA/GTAT)n (TTAA/AATT)n (ATAC/TATG)n 2/11 0/2 0/1 0/3 (CAGG/GTCC)n (GATA/CTAT)n (TGAA/ACTT)n (CACG/GTGC)n 1/1 3/3 2/3 1/1 Penta-, hexanucleotide (TAAAA/ATTTT)n (TTTTG/AAAAC)n (TTTTC/AAAAG)n (GTCTG/CAGAC)n (CTATT/GATAA)n 9/91 1/25 1/42 0/8 1/1 1/1 (GGGGT/CCCCA)n (GGATG/CCTAC)n (CGGGG/GCCCC)n (GGATG/CCTAC)n (GGGAGA)n 1/4 1/1 0/2 1/1 0/3 (CATATA)n (ATGGTG)n 1/1 1/2 families with the new markers CTATT01, TAGA02, and GGAA05, located in the centromeric region of the candidate interval. The new family T2 also had a different 2(244 bp) allele from other families for the marker GGAA05. However, all families had the same haplotype from the marker D16S3086 to the most telomeric marker GT01 (Table 5) : 16 cen-D16S3086: allele 2-TTCC01: allele 4-GATA01: allele 2-D16S421: allele 3-TTTA001: allele 4-CATG003: allele 4-D16S3085: allele 2-D16S3107: allele 7-AAT01: allele 2-D16S3025: allele 4-TCTA01: allele 2-CTTT01: allele 8-D16S496: allele 5-D16S3067: allele 5-D16S3141: allele 3-GT01: allele 6-16q ter. This indicates that a new critical interval of this disease is a region between GGAA05 and D16S3095, no more than 3.8 Mb in size ( Fig.1 and Table 5 ). Among 16 markers spaced in the new critical interval 10 showed significant association with the disease: TTCC01 (P ϭ 0.0462), GATA01 (P ϭ 0.002), D16S3107 (P Ͻ 0.0001), AAT01 (P ϭ 0.0258), TCTA01 (P ϭ 0.0227), CTTT01 (P ϭ 0.0009), D16S496 (P ϭ 0.032), D16S3067 (P ϭ 0.008), D16S3141 (P ϭ 0.011), and GT01 (P Ͻ 0.0001) ( Table 5 ). In particular, three of these markers, D16S3107, CTTT01, and GT01, were in significant linkage disequilibrium (Tables 4, 5 ). In contrast, none of the 38 control individuals had the particular haplotype 2-4-2-3-4-4-2-7-2-4-2-8-5-5-3-6, indicating that this haplotype is significantly associated with the disease and may be useful for molecular diagnosis of 16q-ADCCA.
Screening of dynamic mutations in 16q-linked ADCA type III patients
In the entire sequenced region, we found nine CAG/CTG repeats that have more than seven repeat units by RepeatMasker (Fig. 1) . Four of these were seen in the coding region of three genes, the E2F4 gene (Ginsberg et al. 1994 ), CTGB43a mRNA, and the NFAT5 gene (LopezRodriguez et al. 1999; Hebinck et al. 2000) . CAG repeats in CTGB43a and NFAT5 encode polyglutamine tracts and a CAG repeat in E2F4 is translated into a polyserine stretch. The other two CAG/CTG repeats have already been annotated as polymorphic CAG repeats in the Cooperative Human Linkage Center (CHLC) database (www.chlc.org). The remaining three CAG/CTG repeats, newly identified in this study, were not located in any known genes. Amplifying these nine CAG/CTG repeats revealed that none of them were expanded in our patients with 16q-linked ADCA type III. Direct sequencing of the three genes, the E2F4 gene, CTGB43a mRNA, and the NFAT5 gene, disclosed that there are also no mutations in the coding regions of these genes.
Similarly, we tested 30 trinucleotide repeats, 32 tetranucleotide repeats, and 9 penta-or hexanucleotide repeats for polymorphism in control individuals (Table 2) . However, we have so far not detected any abnormal expansions in 16q-linked ADCA type III patients.
Discussion
In the present study, we constructed a 4.8-Mb physical map consisting of 38 BAC clones covering the candidate region between D16S3043 and D16S3095 (Takashima et al. 2001 ). When we started constructing this contig, very few BAC or yeast artificial chromosome clones had been mapped to this region. In addition, the precise order of microsatellite DNA markers, used in examining the haplotype in our previous set of six families with ADCA type III, was not known (Dib et al. 1996; Takashima et al. 2001) . By constructing the physical map of the candidate interval, we now know that the entire length of the interval is no more than 4.8 Mb, and we further refined the critical interval of 16q-linked ADCA type III by the exact order of DNA markers shared among our affected individuals.
By applying the RepeatMasker program, we discovered 11 new highly polymorphic DNA markers that could be used to analyze haplotypes in our eight families. In the present study, we added two new 16q-linked ADCA type III families for haplotype analysis. This allowed us to further narrow a critical interval that shows a common, "founder" haplotype flanked by GGAA05 and D16S3095. The size of this new critical region was estimated to be 3.8 Mb. The present finding not only refines the candidate interval of this disease, but also corroborates our previous finding of a founder effect in the Japanese families with 16q-linked ADCA type III. In addition, analysis of this common haplotype would be useful for the molecular diagnosis of 16q-linked ADCA type III, which was previously diagnosed only with linkage analysis. Because large informative families are fairly uncommon for such a late-onset disease, finding a diagnostic haplotype would be important.
After refining the critical interval, we next searched a causative mutation in our patients. Because 16q-linked ADCA type III showed a mild phenomenon of anticipation, in that difference in the age-of-onset between parents and offsprings was 4.9 years (Nagaoka et al. 2002) , we first searched for an expansion of trinucleotide CAG/CTG repeats detected by the software RepeatMasker, although none of the nine CAG/CTG repeats in the entire candidate region were expanded. When we tested the threshold of detecting CAG/CTG repeat sequence by the RepeatMasker program, we found that the program faithfully detected CAG/CTG repeats with more than six repeat units. Therefore, it seems probable that the CAG/CTG repeat, which has at least six repeat units in the normal population, is not expanded in our patients with 16q-linked ADCA type III. The smallest CAG/CTG repeats that are known to cause human neurodegenerative disease are the SCA6 gene and the myotonin protein kinase (MtPK) gene (Strachan and Read 1996; Zhuchenko et al. 1997; Ishikawa et al. 1997) . These repeats are as small as 4 to 6 repeats in the normal population, and they expand to more than 20 repeats in SCA6 and more than 50 repeats in myotonic dystrophy type 1 (Strachan and Read 1996; Zhuchenko et al. 1997; Ishikawa et al. 1997) . Considering that the threshold of detecting CAG/CTG repeats in our system is high, the present finding might indicate that the cause of the 16q-linked ADCA type III is not the expansion of the CAG/CTG repeat.
We also searched for any expansion of tri-, tetra-, penta-, or hexanucleotide repeats, as the ATTCT repeat expansion in SCA10 or the complex CCTG repeat expansion in myotonic dystrophy type 2 (Liquori et al. 2001 ). However, we did not observe any expansion of repeat sequences among a group of repeats that showed polymorphism in the general population. These observations further indicate that 16q-ADCA type III may be caused by a mutation other than a repeat expansion, such as a missense mutation. If this is proven to be true, the mild anticipation observed in our families might be caused by another mechanism, as in SPG4 (Hazan et al. 1999) . Obviously, it is still possible that a certain repeat that has a small repeat unit not detected by the RepeatMasker is specifically expanded in our patients. We also do not preclude the possibility of pathogenic expansion of a certain repeat hidden in the remaining small regions, whose nucleotide sequences have not been published. Screening not only dynamic expansion, but also other types of mutation is needed to discover the cause of 16q-linked ADCA type III. Finally, the fruitfulness of this study may be important not only for 16q-linked ADCA type III, but also for other diseases linked to this chromosomal region. The finding of 11 new polymorphic markers as well as the present BAC contig in chromosome 16q22.1 might be valuable for diseases linked to 16q22.1, such as candidate tumor suppressor genes in breast cancer (Callen et al. 2002) .
In conclusion, the finding of a complete BAC contig in 16q22.1, a number of new polymorphic markers, and a common haplotype in 16q-ADCA type III is very useful information for identifying the mutation for 16q-linked ADCA type III. Identification of the disease gene will greatly facilitate diagnosis of SCA patients and will also have an impact on our understanding of complex molecular mechanisms underlying ADCAs.
